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Acetylcholine is the main neurotransmitter at the mammalian
neuromuscular junction (NMJ) where nicotinic acetylcholine recep-
tors mediate the signaling between nerve terminals and muscle
fibers. We show that under glutamatergic transmission, rat NMJ
switches from cholinergic type synapse to glutamatergic synapse.
Connecting skeletal muscle to the lateral white matter of the spinal
cord by grafting the distal stump of the transected motor nerve
produced functional muscle reinnervation. The restored neuromus-
cular activity became resistant to common curare blockers but
sensitive to the glutamate -amino-3-hydroxy-5-methyl-4-isox-
azolepropionic acid receptor antagonist. Analysis of the regener-
ated nerve disclosed new glutamatergic axons and the disappear-
ance of cholinergic fibers. Many axons belonged to the supraspinal
neurons located in the red nucleus and the brainstem nuclei.
Finally, the innervated muscle displayed high expression and
clustering of -amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor subunits glutamate receptors 1 and 2. Our data
suggest that supraspinal neurons can target skeletal muscle, which
retains the plasticity to generate functional glutamatergic NMJ.
glutamate  neuromuscular junction  red nucleus
Traumatic paraplegia caused by spinal cord injury is still anirreversible condition. So far, there is no medical or surgical
treatment capable of curing paraplegia. The CNS is ‘‘nonper-
missive’’ for the advancement of injured axons because of an
abundance of growth-inhibitory molecules in the myelin and the
glial scar (1–3). In addition, there are no growth-promoting
factors at the neuronal growth cone or at the somata. However,
when peripheral nerves (PN) are directly grafted into the CNS,
central axons can progress throughout the peripheral endoneural
tubes, suggesting they can regenerate in an appropriate envi-
ronment (4–7). The central fibers that are diverted into a nerve
graft implanted within a healthy structure derive from neurons
axotomized during the grafting procedure and not from unin-
jured neurons spared by nerve graft implantation (8). Regrowth
ceases as soon as axons contact the CNS milieu again. Various
studies have demonstrated that central axons can elongate within
autologous PN grafted into the spinal cord and form functional
synapses with skeletal muscles, leading to motor and sensory
recovery (7, 9–11). Spinal cord neurons, as well as the midbrain
and brainstem neurons that originate the rubrospinal, vestibu-
lospinal, and reticulospinal tracts, are endowed with a high
capability of axonal regeneration into PN transplants (12–15).
Thus, in an attempt to bypass a spinal cord lesion by connecting
descending motor fibers with skeletal muscles, muscular nerve
branches were inserted into the severed lateral bundle of monkey
spinal cord (11). The new connection produced muscle reinner-
vation and restored motor function. This result raised the
possibility that the regrowth of axons descending from central
noncholinergic neurons and cut during the grafting procedure
could be responsible for functional muscle reinnervation. Here
we tested this hypothesis by connecting the distal stump of a
transected rat motor nerve with lateral white matter. An autol-
ogous sural nerve graft was implanted into the acutely severed
lateral white matter of the spinal cord and connected to the
transected nerve of the internal obliquus abdominis muscle. We
found the grafting of the motor nerve into the lateral bundle of
the spinal cord led to a new glutamatergic innervation of skeletal
muscle, replacing the original cholinergic one (16). By electro-
physiological, molecular, and immunohistochemical analysis, we
show that reinnervated muscles were reprogrammed by su-
praspinal neurons to organize functional glutamatergic neuro-
muscular junctions (NMJ).
Materials and Methods
Surgical Procedure. Experiments were performed on 30 adult
male Sprague–Dawley rats (350–400 g). Rats received carprofen
(8 mgkg) and, 10 min later, they were anesthetized with
tiletamine (16 mgkg) and zolazepam (16 mgkg). All experi-
mental and surgical procedures conformed to the National
Research Guide for the Care and Use of Laboratory Animals
and were approved by the Animal Research Committees of the
University of Brescia. All efforts were made to minimize both
the suffering of the animals and the number of animals used. A
laminectomy was performed to expose the T10-L1 cord segment,
and a 2-mm-deep incision was made in the lateral funiculus of
the right T11-T12 spinal cord. A stump of a PN, 50 mm long,
taken from the sural nerve of the same animal, was inserted1.5
mm into the cord incision. The graft was secured by tying a 9-0
suture through the epineurium of the PN and the dura mater.
The motor nerve innervating the right internal obliquus abdo-
minis muscle was transected, and the distal stump (20 mm long)
was anastomosed to the free end of the grafted nerve by an 11-0
nylon suture. Postoperative treatment with enrofloxacine (10
mgkg per day) was carried out for 6 consecutive days.
A schematic representation of the surgical procedure is shown
in Fig. 5, which is published as supporting information on the
PNAS web site.
Electrophysiological Recordings. Two months after graft implanta-
tion into the right lateral funiculus of the spinal cord, rats were
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monitored for muscle reinnervation and function by an electro-
myographic device (Nicolet Biomedical, Madison, WI). Rats were
deeply anesthetized and mechanically ventilated. Control and re-
innervated internal obliquus abdominis muscles were exposed, and
compound muscle action potentials (CMAP) were measured in
response to direct nerve stimulation. Rats were injected with
vecuronium (800 gkg, i.v.) or with GYKI 52466 (10 mgkg, i.p.).
The nerve stimulation and CMAP recording in reinnervated and
control muscle were performed 30 min after drug injection. In the
animal group that received both antagonists, muscle responsiveness
to nerve stimulation was recorded without drugs, after vecuronium
administration, and finally after GYKI 52466 administration. See
Supporting Text, which is published as supporting information on
the PNAS web site for details.
Immunohistochemical Analysis. Sixty days after nerve grafting, rats
were perfused with a 4% paraformaldehyde solution. Six-
micrometer muscle sections were processed for immuno-
histochemistry with antibodies recognizing GluR1 (2 gml,
Chemicon) and III tubulin (1:1,500, Promega). Sections of
control and grafted nerves were reacted with antibodies recog-
nizing choline acetyltransferase (ChAT) (1:1,000, Chemicon),
III tubulin (1:1,500, Promega), vesicular glutamate transporter
1 (VGluT-1) (1:5,000, Chemicon), and VGluT-2 (1:2,000, Syn-
aptic Systems, Goettingen, Germany). Sections were incubated
in PBS containing the CY2-, CY3-, or tetramethylrhodamine B
isothiocyanate-conjugated secondary antibodies for 1 h at room
temperature. Fluorescence was observed by confocal laser scan-
ning (Bio-Rad 1024) microscopy. See Supporting Text for details.
Western Blot Analysis.Protein extracts were processed forWestern
blot analysis by using antibodies recognizing ChAT (1:200,
Chemicon), vesicular acetylcholine (ACh) transporter (VAChT)
(dilution 1:100, Chemicon), VGluT-1 (1:500, Chemicon),
VGluT-2 (1: 2,000, Synaptic Systems), GluR1 (1:100, Chemi-
con), GluR2 (1:200, Chemicon), GluR3 and -4 (1:250, Santa
Cruz Biotechnology), NR1 (1:1,500, Chemicon), and -tubulin
(1:1,500 NeoMarkers). See Supporting Text for details.
RT-PCR Analysis. Muscle specimens taken in regions enriched of
nerve endings were analyzed by RT-PCR experiments to identify
the mRNA transcripts for GluR subunits. Different sets of
primer pairs, together with the primer for -actin, were used as
an internal standard. An Agilent Technologies (Palo Alto, CA)
2100 bioanalyzer was used for semiquantitative RT-PCR analysis
(17). See Supporting Text for details.
Retrograde Tracing. The retrograde tracing in the regenerated
nerve was performed by injecting the cholera toxin -subunit
(CT, 1 mgml, List Biological Laboratories, Campbell, CA)
into the reinnervated obliquus muscle (18). Six days later, the
animals were perfused, and CT was immunodetected in sec-
tions from brain and spinal cord by using the anticholeragenoid
antibody (1:4,000; List Biological Laboratories). See Supporting
Text for details.
Results
Electrophysiological Recording of Neuromuscular Activity in Reinner-
vated Rats. Sixty days after nerve implantation into the right
lateral funiculus of the spinal cord, rats were monitored for
muscle reinnervation and function. Obliquus muscles at both
reinnervated and controlateral control sides were exposed, and
we recorded the CMAPs in response to direct nerve stimulation
(Fig. 1 and Table 1). The reinnervated muscles efficiently
responded to nerve electric stimulation, although they showed
CMAPs of lower amplitude and longer latency than the control
sides. After the first stimulation, a group of rats was injected with
the competitive neuromuscular blocking agent vecuronium (800
gkg, i.v.), and muscle contractility was again recorded. As
expected, the control side was completely blocked by the appli-
cation of the nicotinic receptor antagonist. Conversely, the
reinnervated muscle appeared to be totally insensitive to the
curare application (Fig. 1A). The electrophysiological response
of reinnervated muscles resistant to vecuronium application was
subsequently blocked by the glutamate -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor antagonist (AMPA)
receptor antagonist GYKI 52466 (19, 20), administered at 10
mgkg i.p. (Table 1). To confirm the efficacy of AMPA receptor
blockade in inhibiting CMAP generation in reinnervated
obliquus muscles, the effect of GYKI 52466 was tested in another
group of rats just after the first nerve stimulation. Even in these
cases, the contractility of reinnervated muscle was efficiently
blocked by theAMPA receptor antagonist, whereas the response
of the controlateral control side was unaffected (Fig. 1B). A
quantitative analysis of data obtained in the two groups of rats
is reported in Table 1.
These results show that the connection of the distal stump of
a transected motor nerve with the lateral funiculus of the rat
spinal cord produces an effective reinnervation of skeletal
muscle. The insensitivity of reinnervated muscle to vecuronium
and its acquired sensitivity to a selective blocker of AMPA
receptor subtypes suggest that reinnervated muscles have be-
come responsive to glutamatergic transmission.
Evaluation of Cholinergic and Glutamatergic Gene Expression in
Grafted Nerves and Reinnervated Muscles. To explore the hall-
marks of the muscle-innervating fibers grown into the nerve
graft, we investigated the expression of two specific markers
for cholinergic neurons, ChAT and VAChT. Western blot
analysis was carried out in homogenates of specimens taken
from the portion of the obliquus muscle receiving nerve
branches. As shown in Fig. 2G, templates from reinnervated
muscle revealed a lack of both ChAT and VAChT proteins
when compared with the controlateral control tissue. We then
investigated the possible expression of VGluT-12, which are
markers of glutamatergic neurons and axon terminals in CNS.
The immunoblot analysis showed a significant expression of
both VGluT-1 and -2 in reinnervated muscle but not in the
control obliquus muscle. To corroborate these results, we
performed an immunof luorescence staining of nerve sections.
The staining for III tubulin, a selective marker of neuronal
Fig. 1. Electrophysiological recording of muscle activity in response to direct
stimulation of control and grafted nerve. (A) Representative recordings of
CMAPs in control and reinnervated muscle. The i.v. injection of vecuronium
completely blocked muscle response to control nerve stimulation but not
muscle response to stimulation of grafted nerve (Reinnervated). Next, admin-
istration of the AMPA receptor antagonist GYKI 52466 totally abolished the
muscle response resistant to vecuronium (Table 1). (B) In these experiments,
GYKI 52466 was administrated after the first CMAP recording. GYKI 52466 did
not modify the control muscle response but totally prevented the response of
reinnervated muscle. Traces are from a representative experiment. The stim-
ulus strength was always adjusted to obtain maximal CMAP amplitude. Mea-
surement of mean SD of CMAPs amplitude and area are reported in Table 1.








microtubules, showed extensive growth of neuronal axons in
the grafted nerve. The ChAT antibody was used to double-
label the cholinergic fibers, whereas VGluT-12 antibodies
were used to stain glutamatergic neurites. As shown in Fig. 2A,
ChAT colocalized with III tubulin in many of the fibers
present in the control nerve, whereas no specific signal for
ChAT was found in sections from grafted nerve (Fig. 2B).
Conversely, VGluT-1 (Fig. 2 C and D) and VGluT-2 (Fig. 2 E
and F) immunostaining was clearly evident in certain localized
regions of grafted nerve (Fig. 2 D and F), whereas it was nearly
undetectable in sections from control nerve (Fig. 2 C and E).
These data suggest that muscle reinnervation was mainly
operated by glutamatergic fibers.
We then analyzed the expression of different glutamate
receptor (GluR) subtypes in parallel templates taken from
muscle regions enriched with nerve endings. The RT-PCR
analysis revealed a lack of NMDA receptor subunit NR1 in both
control and reinnervated obliquus muscles but a constitutive
expression of AMPA receptor subunits (Fig. 3A). In particular,
the mRNA levels for GluR12 subunits displayed a trend to
increase in reinnervated tissue, whereas no increase was found
in GluR34 expression levels. Immunoblot analysis of GluRs in
homogenates from control and reinnervated muscles confirmed
the lack of NR1 subunit in both templates and the significant
increase of GluR12 proteins in reinnervated muscles (Fig. 3B).
Conversely, GluR34 were hardly detectable in either specimens
(Fig. 3B). The confocal immunofluorescence analysis of GluR1
showed spread punctuate signals in control tissue but large
aggregates of immunofluorescence in reinnervated muscle that
only partially colocalized with III tubulin staining (Fig. 3C).
The images were indicative of clusters of postsynaptic AMPA
receptors innervated by III tubulin-positive presynaptic axons.
This physiological and molecular evidence suggests that skeletal
muscle can be reinnervated by glutamatergic neurons and may
respond to the glutamatergic signal by generating functional
glutamatergic NMJ.
Injection of CT into Reinnervated Muscle Produced a Retrograde
Labeling of Brainstem and Red Nucleus Neurons.To obtain a labeling
of neurons extending their axons into the PN graft, the retro-
grade tracer CT was microinjected into the obliquus muscle.
Neuroanatomical tracing confirmed that axons elongated within
the PN graft belonged to supraspinal neurons. We analyzed the
spinal cord segments either rostral or caudal to the graft
implantation, the motor cortex, and those supraspinal regions of
the midbrain and brainstem that mainly contribute to the
descending pathways in the lateral spinal cord. No labeled
neurons were found in the spinal cord or the cortex. Most
retrograde labeling was found in red nucleus neurons or in
neurons belonging to the medullary reticular formation and
vestibular complex. Labeled neurons were found in the nucleus
ambiguus, the dorsal and ventral medullary reticular nuclei, and
the nucleus gigantocellularis (Fig. 4 A and B). In the red nucleus,
most neurons were labeled at the controlateral side to the nerve
Table 1. CMAP response to nerve stimulation
Control Reinnervated
Amplitudes, mV Areas, mVms Amplitudes, mV Areas, mVms
Expt. 1
No drug 8.36  5.11 10.57  5.84 3.87  3.70 4.83  3.45
Vecuronium 0*** 0**** 2.96  2.96 4.88  4.15
GYKI — — 0* (n  5) 0* (n  5)
Expt. 2
No drug 8.70  5.34 12.40  6.03 4.60  4.32 5.50  5.56
GYKI 8.52  5.48 11.62  5.94 0** 0*
Measurement of means and SD of CMAP amplitude and area in control and reinnervated muscle. Vecuronium
and GYKI 52466 were administered as reported in the Fig. 1 legend. In the first set of experiments, GYKI 52466
abolished muscle response resistant to vecuronium. In the second set of experiments, GYKI 52466 prevented
reinnervated muscle response in the absence of vecuronium. The difference of amplitude and area was examined
with a paired Student’s t test. Expt. 1, n 9; Expt. 2, n 8. *, P 0.05; **, P 0.02; ***, P 0.01; ****, P 0.001
vs. no drug.
Fig. 2. Analysis of cholinergic and glutamatergic markers in control and
grafted nerves. (A and B) Confocal images of control (A) and grafted (B) nerve
sections double-labeled with antibodies to ChAT (Cy3, red) and III tubulin
(Cy2, green). (C and D) VGluT-1 (Cy3, red) and III tubulin (Cy2, green) were
double-labeled in control (C) and grafted (D) nerves. (E and F) VGluT-2 (Cy3,
red) and III tubulin (Cy2, green) were double-labeled in control (E) and
grafted (F) nerves. In Merge, white arrows indicate colocalization of III
tubulin and ChAT or VGluT. (Bar, 12m.) (G) Western blot analysis of proteins
from control (C) and reinnervated (R) muscle with antibodies directed to
ChAT, VAChT, VGluT-1, and VGluT-2. Membranes reprobed with antibodies to
-tubulin showed equal amounts of loaded proteins.
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graft, although a few neurons were also labeled at the ipsilateral
side (Fig. 4 C and D).
Discussion
Mammalian NMJ is believed to be a unique cholinergic synapse
where ACh is the main neurotransmitter activating postsynaptic
nicotinic ACh receptors (16, 21). Conversely, invertebrate NMJ is
served by glutamate as major excitatory neurotransmitter (22). The
most striking finding of our study is that, under glutamatergic
innervation, the mammal NMJ can switch from cholinergic-type to
glutamatergic synapse. We found that the connection of the
obliquus abdominis muscle nerve with the lateral bundle of rat
spinal cord by a PN graft restored a functional muscle innervation.
This was revealed by the trophic appearance of reinnervatedmuscle
and the electrophysiological analysis of neuromuscular activity. In
line with previous evidence (11), 2 months after nerve grafting, the
muscle responded to direct stimulation of the motor nerve. The
data obtained from CMAP measurements suggest that the pro-
portion of successfully reinnervatedmuscle fibers was largely above
one-third, but this is an indirect measure. We plan to carry out
intracellular recordings to finely document the percentage of
muscle fibers that are functionally reinnervated and that generate
excitatory postsynaptic potentials. The reinnervated muscles ap-
peared to be insensitive to common curare-mediated blockade
when comparedwith the control one.Muscle resistance to nicotinic
blockers strongly suggested that a neurotransmitter other thanACh
was responsible for NMJ activation. Indeed, we found that rein-
nervated muscle was completely paralyzed by selective blockers of
glutamate AMPA receptor subtypes. The systemic administration
of the AMPA receptor antagonist GYKI 52466 efficiently pre-
vented muscle contraction in response to nerve stimulation on the
nerve graft side but not the control side. The replacement of
ACh-mediated transmission at the NMJ by a glutamatergic trans-
mission was consistent with data from immunofluorescence anal-
ysis of the grafted nerve. Clear ChAT immunoreactivity was found
in the control motor nerve, whereas ChAT signals were nearly
undetectable in the grafted one. Conversely, the labeling ofVGluTs
that are markers of glutamatergic innervation (23) disclosed high
protein expression in grafted nerves, but this was negligible in the
controls.
Taking into consideration the primary role of ACh in acti-
vating NMJ, recent research has proposed the participation of
glutamate in modulating cholinergic transmission. A glutamate-
like immunoreactivity has been found at the level of NMJ and
motor nerve terminals, suggesting glutamate as a possible co-
transmitter of ACh in motoneurons (24, 25). The application of
glutamate to strips of rat diaphragm has been shown to contrib-
Fig. 3. Expression analysis of GluRs in control and reinnervated muscle. (A)
RT-PCR analyses of GluR1, GluR2, GluR3, GluR4, and NR1 transcripts in motor
end plate of control (C, open bar) and reinnervated (R, black bar) obliquus
muscles. The gel-like images produced by Agilent Bioanalyzer 2001 are shown
for the coamplification of -actin and the different GluR transcripts. Histo-
grams show the means of six individual experiments and standard error. For
NR1 analysis, the amplification product from rat cerebral cortex (Cx) was used
as a positive control. Statistical analysis was performed by using two-tail
Student’s t test. (*, P  0.05). An example of electropherogram traces of
-actinGluR1 coamplification is reported (Bottom Right). Upper and lower
markers are used as internal standards to eliminate sample to sample varia-
tion, and calculate size and concentration of each PCR product. (B) Western
blot analysis of GluR subunits NR1, GluR1, GluR2, GluR3, GluR4, and of
-tubulin in proteins extracts from control (C) and reinnervated muscles (R).
(C) Confocal images of control and reinnervated muscle double labeled with
antibodies to GluR1 (Cy2, green) andIII tubulin (Cy3, red). A punctuate GluR1
staining was evident in control sections. A clustering of GluR1 immunofluo-
rescence appeared in reinnervated muscle at the end of a III tubulin-positive
axon.
Fig. 4. Transverse sections through medullary reticular formations and red
nucleus showing retrograde labeling of supraspinal neurons extending axons
into the grafted nerve. Two months after PN grafting, the retrograde tracer
CT was microinjected in the reinnervated muscle. (A) A section from the
medullary reticular formation showing the staining of neurons in the nucleus
gigantocellularis. Higher-magnification micrograph (Inset) is shown in B. A
section from midbrain (C) showing a number of neurons labeled in the red
nucleus controlateral to the grafted side and fewer cells stained at the
ipsilateral side. Higher-magnification micrograph of controlateral red nucleus
(Inset) is shown in D. (Bar, 650 m in A and C; 200 m in B and D.)








ute to the maintenance of the resting membrane potential (26)
and to inhibit the nonquantal release of ACh from nerve endings
(27). Glutamate effects may be mediated by activation of
postjunctional NMDA receptors to induce sarcoplasmic synthe-
sis and retrograde diffusion of NO from muscle cells (27).
However, because glutamate is a ubiquitous intermediate in
cellular metabolism, only the recent identification of VGluTs has
allowed reliable investigation on glutamate as neurotransmitter.
Three types of VGluTs, VGluT-1, -2, and -3, have been identified
in the CNS (23). Although VGluT-12 transcripts have been
detected in rat spinal motoneurons (28, 29), no VGluT-12
proteins have been found to colocalize with VAChT (28, 30) or
ChAT (31). Recent studies demonstrating VGluT-2 immuno-
staining in motoneuron collateral axons projecting to layer VII
of the spinal cord (28, 32) confirmed the lack of VGluT-2 and
glutamatergic transmission in the cholinergic projections to the
NMJ. Furthermore, studies on VGluT-3 expression at the skel-
etal muscle endplates gave contradictory results (33, 34). The
difficulty in demonstrating VGluT expression at the cholinergic
synapses indicates that mechanisms responsible for the high
concentration of glutamate at the NMJ still need to be clarified
or their identification requires more sensitive investigation tools.
In line with this evidence, we found no VGluT-12 immunore-
activity either in nerve sections or endings from control cases.
Conversely, both VGluT-1 and -2 appeared in grafted nerve and
its target muscle, giving unambiguous evidence of the growth of
glutamatergic axons therein. A wider neurochemical analysis of
grafted nerve will possibly disclose the growth of additional
nonglutamatergic axons not examined in this study.
VGluT-12, but mainly VGluT-2, are largely distributed in the
lateral white matter of the spinal cord (31, 35), where they label
glutamatergic fibers, including the descending afferents from glu-
tamatergic supraspinal neurons. Interestingly, expression of
VGluT-2 has been found in midbrain and brainstem nuclei pro-
jecting to the spinal cord, including the red nucleus, reticular
formation, and vestibular complex (35–37). In addition, VGluT-1
expression was specifically detected in cells of the gigantocellular
reticular nucleus (38). Red nucleus and brainstem neurons extend
their axons along the lateral white matter of the spinal cord to form
rubrospinal, reticulospinal, and vestibulospinal tracts (18, 39–41).
We found that a number of these neuronswere retrogradely labeled
byCT application at themuscular synaptic terminals of the grafted
nerve, demonstrating they were primarily involved in the new
glutamatergic innervation of obliquus muscle. No labeled neurons
were found in the cerebral cortex or in spinal cord segments either
rostrally or caudally to the nerve graft site. This finding provides
evidence that brain glutamatergic neurons can directly synapse with
mammal skeletal muscle to drive motor activity.
The specification of neurotransmitter and receptor types is a
crucial phenomenon for nervous system development and regen-
eration, enabling communication between the presynaptic neuron
and the postsynaptic target cell (42, 43). In embryonic neurons,
plasticity of the transmitter phenotype, implying replacement of
excitatory transmitters with inhibitory ones, occurs in response to
neuronal activity (44). Likewise, it has been shown that sympathetic
preganglionic cholinergic fibers can directly reinnervate the smooth
muscle of the nictating membrane in adult cats. The muscle
activation relies on the switch of the preganglionic fibers from a
cholinergic to a noradrenergic phenotype (45). In addition, ‘‘nor-
mally glutamatergic’’ mossy fibers projecting to hippocampal CA3
pyramidal cells have been found to generate GABAergic postsyn-
aptic potentials after kindled seizure, as a possible homeostatic
reaction to hyperexcitability (46). Open questions arising from
transmitter specification plasticity are whether and how changes in
presynaptic neurotransmitter phenotype correspond to changes in
the expression of postsynaptic transmitter receptors, to achieve
functional synapse formation. Another open question is whether
transmitter specification can reroute neurons to make synaptic
connections with suitable targets, or whether it is itself regulated by
specific targets. Our results strongly suggest that glutamatergic
postsynaptic specification occurs under glutamatergic innervation
of skeletal muscle. The pharmacological analysis of receptors
involved in activation of reinnervated NMJ strikingly indicates the
presence and function of AMPA-type GluRs. We show that the
muscle response to nerve stimulation was totally blocked by the
selectiveAMPAreceptor antagonistGYKI 52466 (19, 20). Because
AMPA receptors are tetrameric heteromeric complexes of four
homologous subunits,GluR1–4, we analyzed the expression of each
AMPA receptor gene. In the control muscle all of GluR1–4,
transcripts were detected together with very low levels of GluR12
translation products. In reinnervated muscle, GluR12 subunits
displayed an upward mRNA expression trend with a higher signif-
icant occurrence at the protein level. Hence, both GluR1 and -2
proteins, hardly detectable in the control muscle, displayed marked
expression after reinnervation by glutamatergic axons. Moreover,
the immunofluorescence analysis of GluR1 in reinnervated muscle
revealed large clusters of postsynaptic AMPA receptors, a key
feature of a specialized postsynaptic apparatus (16, 42).
An intriguing subject of future investigation would be to find
molecules and mechanisms responsible for synapse assembly be-
tween brain neuronal terminals and skeletal muscle. Although the
expression of AMPA receptors in mammalian muscle has never
been investigated, the NMDA receptors were found to mediate the
modulatory effects of glutamate at the NMJ in the rat diaphragm
(47).However, studies based on the immunocytochemical detection
of NR1 showed that the expression of the NMDA receptor cannot
be generalized to all skeletal muscles (48) and may vary with
muscle-type fiber composition.We failed to detect anyNR1protein
or mRNA in obliquus muscle either before or after glutamatergic
innervation. This suggests that activation of glutamate AMPA, but
not NMDA receptors, wasmainly involved in the signaling between
nerve terminals and reinnervated muscle. The presynaptic elimi-
nation of cholinergic input did not cause the disappearance of the
nicotinic ACh receptor mRNAs (data not shown). Experiments
addressed to investigate changes of nicotinic NMJ in muscle
subjected to glutamatergic reinnervation would add information
about the possible colocalization of GluR with the ACh receptor
and the potential role of preexisting pathways in guiding new
glutamatergic projections.
It has been established that glutamate has a primary role in
neuromuscular transmission of organisms phylogenically distant
from mammals, such as invertebrates, including insects and mol-
lusks (22, 49, 50). In addition, glutamate acts as cotransmitter of
ACh by regulating the development and function of cholinergic
synapse in fishes and amphibians (51–53). Our study suggests that
mammal skeletal muscles retain the memory of ancestral glutama-
tergic transmission together with the capability to remodel and
reorganize the molecular patterning of NMJ postsynaptic mem-
brane to the glutamatergic input. A future challenge, therefore,
would be to define signals and molecular mechanisms responsible
for glutamatergic synapse formation and maintenance at mammals
NMJ and to understand how these mechanisms interact to achieve
differentiation of postsynaptic specialization and restoration of
muscle activity. Understanding the enormous potentiality of CNS
plasticity in regulating motor function would unravel new strategies
for intervention in spinal cord injury.
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